Acrivon ipo price
WebNov 15, 2024 · After delaying its offering by a few days, the company sold 7,550,000 shares at $12.50 apiece. It also agreed to sell another 400,000 shares at the IPO price to its top … WebA crivon Therapeutics (ACRV proposed), a cancer biotech aiming to raise $100.3 million, leads a life sciences-focused IPO Calendar of seven deals during this election week. This is the first big IPO ($100 million-plus) to land on the IPO Calendar since Mobileye Global, Inc. ( MBLY) scored its successful IPO in late October.
Acrivon ipo price
Did you know?
WebNov 7, 2024 · A Watertown startup testing a drug licensed from Eli Lilly & Co. in midstage trials has filed for a $100 million IPO. Acrivon Therapeutics Inc. is scheduled to pull off the deal this week ... Web$8.79 (As of Thursday Closing) General Information Description Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
Web2 days ago · Since the IPO on November 15, 2024, Acrivon Therapeutics, Inc.'s market cap has decreased from $235.12M to $192.68M, a decrease of -18.05%. That is a compound … WebApr 12, 2024 · According to analysts' consensus price target of $21.00, Acrivon Therapeutics has a forecasted upside of 138.9% from its current price of $8.79. Amount of Analyst Coverage Acrivon Therapeutics has …
Web27 rows · Business: ( Note: Acrivon Therapeutics priced its IPO on Monday night, Nov. 14, 2024, at $12.50 ... WebAcrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates Boston Business Journal 11. 11. 2024 With $100M, startup to bring Lilly-licensed drug into trials Precision Oncology News 11. 11. 2024 Acrivon Therapeutics Raises $100M in Series B Funding See more
WebAcrivon Therapeutics has raised a total of $115.5M in funding over 2 rounds. Their latest funding was raised on Nov 11, 2024 from a Series B round. Acrivon Therapeutics is …
WebAcrivon Therapeutics (ACRV) priced its IPO at $12.50 – far below its initial price range of $16.00 to $18.00 – and sold 7.55 million shares (7,550,000 shares) on Monday night … effective new group in tcshWebNov 8, 2024 · The precision medicine company said in a filing that it plans to offer 5.9M shares priced between $16 and $18, which would raise around $100M if priced at the … effective networking trainingWebRenaissance Capital — Oncology biotech Acrivon Therapeutics prices IPO at $12.50, well below the range Find More Contacts for Acrivon Therapeutics Peter Blume-Jensen CEO, Founder, President Executive Management 1 email found View contacts for Acrivon Therapeutics to access new leads and connect with decision-makers. View All Contacts … containerized airport survelance radarWebNov 15, 2024 · Acrivon Therapeutics (NASDAQ: ACRV) is a clinical-stage oncology company leveraging its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), for the development of its drug pipeline. Use the CB Insights Platform to explore Acrivon Therapeutics's full profile. ... Date of IPO 11/15/2024. Market Cap 0.40B. … containerize active directoryWebApr 10, 2024 · Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the … containerize application using dockerWebAcrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo Finance U.S. markets closed Acrivon Therapeutics, Inc. (ACRV) NasdaqGM - NasdaqGM Real … effective note-taking consists of three partsWebNov 3, 2024 · Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the symbol … containerized batch laundry